Risk factors and prognostic impact of serious immune-related adverse events induced by nivolumab plus ipilimumab combination therapy in patients with non-small cell lung cancer

Tatsumi A. Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Otemae, Chuo-ku, Osaka-shi, Osaka, Japan
tatsumi@pharm.kobegakuin.ac.jp , Nozawa K. Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Chuo-ku, Kobe, Japan , Funatomi K. Faculty of Pharmaceutical Sciences,, Kobe Gakuin University, Chuo-ku, Kobe, Japan , Kadokawa Y. Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Otemae, Chuo-ku, Osaka-shi, Osaka, Japan , Hasegawa S. Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Otemae, Chuo-ku, Osaka-shi, Osaka, Japan , Takeda K. Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Otemae, Chuo-ku, Osaka-shi, Osaka, Japan , Takagi M. Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Otemae, Chuo-ku, Osaka-shi, Osaka, Japan

Comments (0)

No login
gif